鹿得医疗(832278) - 2024 Q1 - 季度财报

Financial Performance - Operating revenue for Q1 2024 was ¥65,987,957.04, a decline of 17.08% year-on-year[11] - Net profit attributable to shareholders dropped by 68.39% to ¥3,888,729.21 compared to the same period last year[11] - Total operating revenue for Q1 2024 was CNY 65,987,957.04, a decrease of 17.1% compared to CNY 79,581,657.02 in Q1 2023[37] - Total operating costs for Q1 2024 were CNY 62,060,081.82, down 11.2% from CNY 69,877,217.46 in Q1 2023[37] - Net profit for Q1 2024 was ¥4,272,576.12, down 61.1% from ¥11,015,825.86 in Q1 2023[40] - Total comprehensive income for Q1 2024 was ¥4,272,576.12, down 61.1% from ¥11,015,825.86 in Q1 2023[40] Cash Flow - Cash flow from operating activities showed a net outflow of ¥22,653,367.65, a decrease of 213.20% year-on-year[11] - Cash inflow from operating activities totaled ¥65,201,461.72 in Q1 2024, down 40.6% from ¥109,804,625.54 in Q1 2023[41] - Operating cash flow for Q1 2024 was negative at -¥23,013,106.94, compared to a positive cash flow of ¥27,245,658.48 in Q1 2023, indicating a significant decline in operational performance[43] - The net increase in cash and cash equivalents for Q1 2024 was -¥4,264,549.87, compared to a positive increase of ¥7,851,547.74 in Q1 2023, highlighting a shift in cash management[44] Assets and Liabilities - Total assets decreased by 2.85% to ¥476,676,119.23 compared to the end of last year[11] - The company’s asset-liability ratio decreased to 17.02% from 19.90% at the end of the previous year[11] - Total liabilities decreased to ¥83,117,072.16 from ¥101,008,234.16, a reduction of about 17.7%[33] - The company's equity increased to ¥393,559,047.07 from ¥389,670,317.86, reflecting a growth of approximately 1.0%[33] Research and Development - Research and development expenses increased by 45.46% to ¥3,170,601.68 due to expansion of the R&D team and increased investment in product development[13] - Research and development expenses increased to CNY 3,170,601.68 in Q1 2024, up 45.5% from CNY 2,179,698.65 in Q1 2023[37] - The company is actively engaged in the development of new products and technologies, although specific details were not disclosed in the provided content[28] Shareholder Information - The total number of ordinary shares is 176,000,000, with 6,664 shareholders[16] - The top ten shareholders hold a combined 71.49% of the shares, with the largest shareholder owning 22.23%[17] - There are no pledges or judicial freezes on shares held by shareholders with over 5% ownership[19] - The company has no outstanding preferred stock issues[20] Related Party Transactions - The company reported a daily related party transaction of CNY 27,269.03 for purchasing raw materials in Q1 2024, against an estimated amount of CNY 3,300,000.00[23] - The company sold products worth CNY 1,266,524.77 to a related party in Q1 2024, compared to an estimated CNY 3,100,000.00[23] - The company has no other major related party transactions or significant asset acquisitions during the reporting period[22] Legal and Compliance - There are no significant legal disputes that could adversely affect the company's operations[23] - The company has complied with all necessary internal review procedures for reported matters[22] - The company has fulfilled all previously disclosed commitments related to stock issuance and price stabilization measures[26] Investment Activities - The company reported a fair value gain of ¥313,966.11 in Q1 2024, compared to a loss of -¥77,930.53 in Q1 2023[40] - Investment activities generated a net cash inflow of ¥8,648,717.30 in Q1 2024, a recovery from a net outflow of -¥18,414,099.54 in Q1 2023[44] - The cash outflow for purchasing fixed assets and other long-term assets was ¥9,796,003.67 in Q1 2024, a decrease from ¥18,534,227.40 in Q1 2023, indicating a more conservative investment approach[43]